Understanding Between Israel Aircraft Industries Ltd. ("IAI") And Scope - Metal Trading & Technical Services Ltd. ("SUPPLIER")Confidential Treatment • October 12th, 2007 • Scope Metals Group Ltd.
RPS STANDARD FORM CONTRACT BY AND BETWEEN THE NEW YORK STATE ENERGY RESEARCH AND DEVELOPMENT AUTHORITY AND NOBLE BELLMONT WINDPARK, LLC Dated: MARCH 14, 2007Confidential Treatment • August 29th, 2008 • Noble Environmental Power LLC • Electric services • New York
This Agreement (“Agreement”) is entered into as of March 14, 2007 (the “Effective Date”) by and between the New York State Energy Research and Development Authority (“NYSERDA”), a public benefit corporation, having a principal business address of 17 Columbia Circle, Albany, New York 12203, and Noble Bellmont Windpark, LLC (“Seller”), a Delaware limited liability company, having a principal business address of 8 Railroad Avenue, Suite 8, Essex, Connecticut 06426. NYSERDA and Seller are each referred to herein as a “Party” and are collectively referred to herein as the “Parties.”
ADVISORY AGREEMENTConfidential Treatment • August 15th, 2011 • Managed Futures Profile MV, L.P. • Commodity contracts brokers & dealers • New York
THIS AGREEMENT, made as of April 30, 2007, among Morgan Stanley Managed Futures DKR I, LLC, a Delaware limited liability company (the “Trading Company”), Demeter Management Corporation, a Delaware corporation (the “Trading Manager”), and DKR Fusion Management L.P., a Delaware limited partnership (the “Trading Advisor”).
RECITALSConfidential Treatment • September 28th, 2004 • Ormat Technologies, Inc. • Electric services • Nevada
FOR MATERIAL BETWEENConfidential Treatment • October 12th, 2007 • Scope Metals Group Ltd.
ADVISORY AGREEMENTConfidential Treatment • August 14th, 2012 • Rjo Global Trust • Commodity contracts brokers & dealers • Illinois
THIS AGREEMENT, made as of March 30, 2012, among RJO Global Trust, a Delaware statutory business trust (the “Fund”), R.J. O’Brien Fund Management, LLC, a Delaware limited liability company (the “Managing Owner”), and Hyman Beck & Company, Inc., a Delaware corporation (the “Trading Advisor”).
AMENDMENT 1 TO THE INHALED COLLABORATION AND OPTION AGREEMENTConfidential Treatment • June 28th, 2018 • Liquidia Technologies Inc • Surgical & medical instruments & apparatus
This Amendment no. 1 to the Agreement (“Amendment”) is made effective as of the 13th day of May 2015 (“Amendment Effective Date”) by and between:
Exhibit 10.3 CONFIDENTIAL TREATMENT REQUESTED BY SYNERON MEDICAL LTD TURN - KEY MANUFACTURING AGREEMENT This agreement is effective as of the 31 of August, 2003 (the Effective Date) by and between: SYNERON MEDICAL LTD., with a principal place of...Confidential Treatment • August 3rd, 2004 • Syneron Medical Ltd. • Electromedical & electrotherapeutic apparatus
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY RESACA EXPLOITATION, INC. FOR CERTAIN PORTIONS OF THIS DOCUMENT. CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS...Confidential Treatment • March 5th, 2010 • Resaca Exploitation, Inc. • Crude petroleum & natural gas
This Agreement is made between SHELL TRADING (US) COMPANY (STUSCO), “Buyer” and RESACA EXPLOITATION, LP. (RESACA), “Seller” whereby each party agrees to sell and deliver and each party agrees to purchase and receive crude oil or condensate under the terms and conditions set forth in Exhibit A and Conoco Inc.’s General Provisions, attached hereto and made a part hereof.
LICENSE AGREEMENTConfidential Treatment • October 31st, 2013 • Glycomimetics Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT dated as of the 7th day of October, 2011 (the “Agreement”) is made between GlycoMimetics, Inc., a Delaware corporation having a place of business at 401 Professional Drive, Suite 250, Gaithersburg, Maryland 20879 (“GMI”) and Pfizer Inc., a Delaware corporation having its principal place of business at 235 East 42nd Street, New York, New York 10017 (“Pfizer”).
ARTICLE I DEFINITIONSConfidential Treatment • April 26th, 2000 • Global Sports Inc • Rubber & plastics footwear • Delaware
INTERNATIONAL BANANA PURCHASE AGREEMENT F.O.B ( PORT OF LOADING) COLOMBIA (URABA AND SANTA MARTA) (as amended through July 14, 2008) (Translation of original, which is in Spanish)Confidential Treatment • November 3rd, 2010 • Chiquita Brands International Inc • Agricultural production-crops • Florida
This International Banana Purchase Agreement is entered by CHIQUITA INTERNATIONAL LIMITED, a company incorporated and existing under the laws of Bermuda, British West Indies, domiciled in the city of Hamilton, Bermuda (hereinafter the “BUYER”) and BANANA INTERNATIONAL CORPORATION, a company incorporated and existing according to the laws of the Republic of Panama, domiciled in Panama City (hereinafter the “SELLER”) according to and in connection with the Stock Purchase Agreement signed by Chiquita International Limited/Chiquita Brands, LLC and Invesmar Limited on June 10, 2004 under the following terms and conditions:
CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT Supplemental Agreement No. 19 to Purchase Agreement No. 2191 between The Boeing...Confidential Treatment • March 17th, 2010 • Copa Holdings, S.A. • Air transportation, scheduled
SAND SUPPLY AGREEMENT1Confidential Treatment • September 2nd, 2016 • Mammoth Energy Services, Inc. • Oil & gas field services, nec
This SAND SUPPLY AGREEMENT (this “Agreement”) is effective as of October 1, 2014 (the “Effective Date”), between Muskie Proppant LLC, a Delaware limited liability company (“Supplier”), and Gulfport Energy Corporation, a Delaware corporation (“Customer”). Supplier and Customer are individually referred to as a “Party” and collectively as the “Parties”).
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed...Confidential Treatment • October 13th, 2015 • Axsome Therapeutics, Inc. • Pharmaceutical preparations • New York
FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT AS OF JUNE 20, HEALTHCARE LIMITED D/B/A ZYDUS CADILA AND KADMON PHARMACEUTICALS, LLC f/k/a THREE RIVERS PHARMACEUTICALS, LLCConfidential Treatment • July 7th, 2016 • Kadmon Holdings, LLC • Pharmaceutical preparations
WHEREAS, Zydus Pharmaceuticals USA. Inc. (“Zydus”)(as Seller), Cadila Healthcare Limited d/b/a Zydus Cadila (“Zydus Cadila”) and Kadmon Pharmaceuticals. LLC f/k/a Three Rivers Pharmaceutical, LLC (“Kadmon”)(as Buyer) entered into, inter alia, an Asset Purchase Agreement dated as of June 20, 2008 (the “Asset Purchase Agreement”), and now desire to amend and restate it;
MATERIALS SUPPLY AGREEMENTConfidential Treatment • July 7th, 2014 • Roka BioScience, Inc. • Laboratory analytical instruments • California
THIS MATERIALS SUPPLY AGREEMENT (the “Agreement”) is made and entered into as of September 10, 2009 (the “Effective Date”) by and between GEN-PROBE INCORPORATED, a Delaware corporation with a principal place of business at 10210 Genetic Center Drive, San Diego, CA 92121 (“Supplier”), and ROKA BIOSCIENCE, INC., a Delaware corporation with a principal place of business at 10210 Genetic Center Drive, Suite 101, San Diego, CA 92121 (“Purchaser”). Purchaser and Supplier may be referred to individually herein as a “Party,” and collectively as the “Parties.”
ContractConfidential Treatment • June 28th, 2018 • Liquidia Technologies Inc • Surgical & medical instruments & apparatus
Confidential treatment has been requested with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
SUPPLY AGREEMENT (MB Global Contract No. [***])Confidential Treatment • June 8th, 2018 • Autolus Therapeutics LTD • Biological products, (no disgnostic substances)
This Supply Agreement (this “Agreement”) is made as of March 23, 2018, by and between Miltenyi Biotec GmbH, having an address at Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany (hereinafter referred to as “Miltenyi”), and Autolus Ltd, having an address at Forest House, 58 Wood Lane, London, W12 7RZ, UK (hereinafter referred to as “Autolus”). Miltenyi and Autolus are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
MASTER DEVELOPMENT AND MANUFACTURING AGREEMENTConfidential Treatment • June 18th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • New York
This Master Development and Manufacturing Agreement (including all appendices hereto, this “Agreement”) is entered into as of February 13, 2018 (the “Effective Date”) by and between Magenta Therapeutics, Inc., a Delaware corporation having offices at 50 Hampshire Street, 8th Floor, Cambridge, MA 02139 (“Magenta”), and Bachem Americas, Inc., a California corporation, having offices at 3132 Kashiwa Street, Torrance, CA 90505 (“Bachem”). Magenta and Bachem may be referred to individually as a “Party” or collectively as the “Parties.”
EXHIBIT 10.8Confidential Treatment • February 12th, 2001 • Riverstone Networks Inc • Computer communications equipment • California
MANUFACTURING DEVELOPMENT AND SCALE-UP AGREEMENTConfidential Treatment • June 28th, 2018 • Liquidia Technologies Inc • Surgical & medical instruments & apparatus • Delaware
This Manufacturing Development and Scale-up Agreement (the “Agreement”) is made as of March 19, 2012 (the “Effective Date”), between Liquidia Technologies, Inc., a Delaware corporation (“Liquidia”) having its principal place of business at Suite 100, 419 Davis Drive, Morrisville, NC 27560 and Chasm Technologies, Inc., a Massachusetts corporation (“Chasm”) with principal offices located at 85 Wagon Rd, Westwood, MA 02090.
UNION LOGO]Confidential Treatment • September 28th, 2004 • Ormat Technologies, Inc. • Electric services
Agreement Number: GEN012900 EXHIBIT 10.17 Licensee InformationConfidential Treatment • June 15th, 2000 • Support Com Inc • Services-computer processing & data preparation • New York
CONFIDENTIAL TREATMENT AMADEUS PRODUCTS AND SERVICES AGREEMENTConfidential Treatment • July 9th, 2012 • KAYAK SOFTWARE Corp • Services-business services, nec • England
Amadeus IT Group, S.A., a Spanish company with principal offices at Salvador de Madariaga, 1—28027 Madrid, Spain (“Amadeus”) including its group entities, and
SECOND AMENDMENT to the Crude Oil Purchase AgreementConfidential Treatment • June 12th, 2015 • Freeport-McMoran Inc • Metal mining
Except as herein changed, altered or amended, all of the terms, provisions, covenants and conditions contained in the Agreement shall remain in full force and effect. The terms and provisions hereof shall be binding upon and inure to the benefit of the Parties hereto, their heirs, representatives, successors and assigns. This Amendment may be executed by the Parties by facsimile or email/PDF which shall constitute an original agreement.
FIRST AMENDED AND RESTATED LICENSE AGREEMENTConfidential Treatment • June 10th, 2016 • Kadmon Holdings, LLC • Pharmaceutical preparations • New York
This FIRST AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”), dated as of September , 2011 (the “Execution Date”) and effective as of August 13, 2010 (the “Effective Date”) by and between Symphony Evolution, Inc., a Delaware corporation (“Symphony”) and Kadmon Corporation, LLC (f/k/a Kadmon Pharmaceuticals, LLC), a Delaware limited liability company (“Licensee”) (each of Symphony and Licensee being a “Party,” and collectively, the “Parties”).
RESEARCH COLLABORATION AND COMMERCIALIZATION AGREEMENTConfidential Treatment • March 5th, 2009 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New Jersey
THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of October 20, 2006 (the “Effective Date”), is entered by and between CELLDEX THERAPEUTICS, INC., a New Jersey corporation, with a principal place of business at 222 Cameron Drive, Suite 400, Phillipsburg, New Jersey, NJ 08865, (“Celldex”) and the LUDWIG INSTITUTE FOR CANCER RESEARCH, a Swiss not-for-profit corporation with a registered office at Stadelhoferstrasse 22, 8001 Zurich, Switzerland, and an office at 605 Third Avenue, 33rd Floor, New York, NY 10158 USA, (“Ludwig”).
CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Confidential Treatment has been requested for portions of this Exhibit. Confidential portions of this Exhibit are designated by [*****]. A complete version of this Exhibit has been filed separately with...Confidential Treatment • December 1st, 2014 • Azul Sa • Air transportation, scheduled • Rio de Janeiro
PETROBRAS DISTRIBUIDORA S.A., with corporate taxpayer ID number [CNPJ] 34.274.233/0001-02, with its-office in the city of Rio de Janeiro, state of Rio de Janeiro, at Rua General Canabarro 500, Ground Floor, 6th and 11th floors (partial), 12th through 16th floors, represented here by its President, Mr. José Lima de Andrade Neto, bearer of drivers license number 26703881-8 – DETRAN/RJ and personal taxpayer ID number [CPF] 102.994.085-15, and by its Consumer Market Officer, Mr. Andurte de Barros Filho, bearer of ID card number 49570D CREA-RJ and personal taxpayer ID number [CPF] 514.048.857-49, from here onwards referred to as “BR,” and, on the other side,
Confidential TreatmentConfidential Treatment • January 19th, 2005 • DryShips Inc. • Deep sea foreign transportation of freight • New York
POLY SILICON SUPPLY AGREEMENTConfidential Treatment • May 9th, 2008 • Sunpower Corp • Semiconductors & related devices
Jupiter CORPORATION LTD, a Hong Kong corporation with its principal place of business at Rm 1206-7 12F, New Victory House, 93-103 Wing Lok Street, Central, Hong Kong (“Jupiter”), and SunPower Corporation, a United States corporation with its principal place of business at 3939 North First Street, San Jose, California 95134 (“SunPower”) hereby enter into this Long-Term Supply Agreement (the “Agreement”) effective as of the date of SunPower’s execution of this Agreement (the “Effective Date”).
ContractConfidential Treatment • April 14th, 2010 • Sims Metal Management LTD • Wholesale-misc durable goods • New South Wales
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO CERTAIN PORTIONS OF THIS AGREEMENT. CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION.
CONFIDENTIAL TREATMENTConfidential Treatment • August 6th, 2007 • Chiquita Brands International Inc • Agricultural production-crops • London
Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such Portions are marked “[*]” in this document; they have been filed separately with the Commission.
CONFIDENTIAL TREATMENT REQUESTED Portions of this exhibit indicated by “[***]” have been omitted, and such omitted portions have been filed separately with the Securities and Exchange Commission (SEC). Confidential treatment has been requested with...Confidential Treatment • November 7th, 2014 • Enerpulse Technologies, Inc. • Motor vehicle parts & accessories • New Mexico
AGREEMENT made this 1st day of October, 2014 by and between Enerpulse Technologies, Inc., with offices at 2451 Alamo Ave. NE, Albuquerque, NM, 87106 (hereinafter, MANUFACTURER), and Green Bridge Technologies LLC, with offices at 54790 Grand River Ave., New Hudson, MI, 48165 (hereinafter DISTRIBUTOR). MANUFACTURER and DISTRIBUTOR may be referred to hereinafter, together, as the “Parties” and individually as a “Party.”
LICENCE AGREEMENT AS AMENDED ON 28 MARCH 2018Confidential Treatment • May 10th, 2018 • Autolus Therapeutics LTD • Biological products, (no disgnostic substances) • England
THIS AGREEMENT was made as of 25 September 2014 (the “Effective Date”), was amended as of 2 March 2016 (the “Amendment Date”), and is amended and restated as of 28 March 2018 (the “Second Amendment Date”)
